Search

Displaying results 161 - 170 of 4265 in total
  1. Drug

    Hydroxyethyl cellulose

    go.drugbank.com/drugs/DB11602
    Approved

    It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic

  2. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. … AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

  3. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

  4. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    [L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births

  5. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  6. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  7. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene.

  8. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    [A230128] HA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections. … HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication.

  9. Drug

    Oxygen

    go.drugbank.com/drugs/DB09140
    ApprovedInvestigationalVet approved

    Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy.

  10. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.